Compile Data Set for Download or QSAR
Report error Found 135 Enz. Inhib. hit(s) with all data for entry = 10697
Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM50561213(CHEMBL4797508 | US11377469, Example 1)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM50561215(CHEMBL4784125 | US11377469, Example 3)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560441(US11377469, Example 7 | ((((2R,3S,4R,5R)-5-(4- (be...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560443(US11377469, Example 9 | (2-((((2R,3S,4R,5R)-5-(6-c...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM50561218(CHEMBL4785716 | US11377469, Example 10)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560446(US11377469, Example 12 | ((((2R,3S,4R,5R)-5-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM50561219(CHEMBL4782125 | US11377469, Example 13)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM50561220(CHEMBL4760944 | US11377469, Example 14)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560449(US11377469, Example 15 | ((((2R,3S,4R,5R)-5-(2-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560450(US11377469, Example 16 | ((((2R,3S,4R,5R)-5-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560451(US11377469, Example 17 | ((((2R,3S,4R,5R)-5-(4-((2...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560452(US11377469, Example 18 | ((((2R,3S,4R,5R)-5-(4-((3...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560455(US11377469, Example 23 | ((((1R,2R,3S,4R)-4-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560456(US11377469, Example 24 | ((((2R,3S,4R,5R)-5-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560457(US11377469, Example 25 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560459(US11377469, Example 27 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560461(US11377469, Example 29 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560462(US11377469, Example 30 | ((((2R,3S,4R,5R)-5-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560463(US11377469, Example 31 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560464(US11377469, Example 32 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560465(US11377469, Example 33 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560466(US11377469, Example 34 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560466(US11377469, Example 34 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560469(US11377469, Example 37 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560470(US11377469, Example 38 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560471(US11377469, Example 39 | ((((2R,3S,4R,5R)-5-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560472(US11377469, Example 40 | ((((2R,3S,4R,5R)-5-(2-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560473(US11377469, Example 41 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560474(US11377469, Example 42 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560475(US11377469, Example 43 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560477(US11377469, Example 45 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560478(US11377469, Example 46 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560479(US11377469, Example 47 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560480(US11377469, Example 48 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560481(US11377469, Example 49 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560483(US11377469, Example 51 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560484(US11377469, Example 52 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560485(US11377469, Example 53 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560490(US11377469, Example 58 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560491(US11377469, Example 59 | ((((2R,3S,4R,5R)-5-(5-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560493(US11377469, Example 61 | (((((2S,3S,4R,5R)-5-(6-ch...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560494(US11377469, Example 62 | (((((2S,3(((((2S,3S,4R,5R...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560495(US11377469, Example 63 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560498(US11377469, Example 66 | (((((2S,3S,4R,5R)-5-(6-ch...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560500(US11377469, Example 68 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560501(US11377469, Example 69 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560502(US11377469, Example 70 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560503(US11377469, Example 71 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560504(US11377469, Example 72 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Target5'-nucleotidase(Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM560505(US11377469, Example 73 | ((((2R,3S,4R,5R)-5-(6-chl...)
Affinity DataIC50: 500nMAssay Description:Assay Reaction ConditionsAssay Volume: 70 μlReaction Volume: 50 μlCD73: 0.3208 nMAMP: 15 μMAssay Buffer: 2 5 mM Tris-HCL, pH 7.4, 0.01...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 135 total ) | Next | Last >>
Jump to: